Recombination Therapeutics LLC and Thomas Jefferson University have synthesized DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.

Guangdong Newopp Biopharmaceuticals Co. Ltd. has identified macrocyclic derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Tibet Haisco Pharmaceutical Co. Ltd. has divulged myosin-2 (MYH2) inhibitors reported to be useful for the treatment of muscular dystrophy.

Haisco Pharmaceutical Group Co. Ltd. has discovered sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Blueprint Medicines Corp. has synthesized Cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Mingsheng Jutai Biotechnology Co. Ltd. has patented β-catenin (CTNNB1)/BCL9 interaction inhibitors reported to be useful for the treatment of cancer and fibrosis.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered estrogen-related receptor α (ERRα; ERR1) inverse agonists reported to be useful for the treatment of cancer, obesity, hypertension, gallstone, osteoporosis, metabolic syndrome, hyperuricemia and Alzheimer's disease.

Blueprint Medicines Corp. has identified cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

A Suzhou Puhe Biopharma Co. Ltd. patent reports new Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors described as potentially useful for the treatment of cancer.